Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
NCT Number: NCT05220033
This study looks at how well the Journey Ahead intervention works in improving coping and communication skills in participants with gynecologic cancers.
This study is active but is not currently recruiting participants.
18 year and older
Female
Interventional
Not applicable
New Brunswick, New Jersey, 08901, United States
Primary goals of this project are:
Objective 1: Phase 1: To collect feedback from patients on CCI online and to assess patient's evaluation of CCI online.
Objective 2: Phase 1: To examine the feasibility and acceptability of a CCI online.
Objective 3: Phase 1/2: To collect preliminary data on changes in distress and coping associated with participation in CCI online.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
Receive information focusing on coping skills for patients diagnosed with gynecologic cancer
Ancillary studies
Time frame: Baseline, two and 6 months post-baseline
Depressive symptoms will be measures with the Beck Depression inventory which is a 21-item scale which has been widely used in studies incorporating cognitive-behavioral interventions. Calculate score bye summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63.
Time frame: Baseline, two and 6 months post-baseline
The MHI-18 has subscales for Psychological Distress (anxiety, depression and loss of behavioral and emotional control) and Well-being. can assess 4 subscales of emotional status like Anxiety, Depression, Behavioral control, and Positive affect. MHI generates one total score. The subscale and total scores range from 0 - 100, with higher scores indicate better mental health
Time frame: Baseline, two and 6 months post-baseline
The Impact of Events Scale (IES) (108) is a 21-item self-report measure focusing on intrusive and avoidant ideation related to ovarian cancer and its treatment. Using a 4-point Likert scale, participants rate how true each statement has been for them during the past week (scale range = 0-75).
Time frame: Baseline, two and 6 months post-baseline
The Functional Assessment of Cancer Therapy - General (FACT-G) (110) is a widely used measure of QOL. The FACT-G is comprised of 27 questions that assess well-being in four domains: physical (PWB), functional (FWB), social/family (SFWB), and emotional (EWB). PWB assesses the physical symptoms; FWB assesses the degree to which the person can participate and enjoy normal daily activities; SFWB assesses social support and communication, and EWB measures mood and emotional response to illness. The domains are summed
Time frame: Baseline, two and 6 months post-baseline
The 26 item Physical function scale of the CARES measure asks patients to rate physical limitations on a 5-point scale. The mean of all items is calculated.
Time frame: Baseline, two and 6 months post-baseline
The acceptance, positive reappraisal, and mental disengagement subscales of the COPE (Carver, Scheier, Weintraub 1989). The scale ranges from 1 = I usually don't do this at all 2 = I usually do this a little bit 3 = I usually do this a medium amount 4 = I usually do this a lot. The scale assess a broad range of coping responses
Time frame: Baseline, two and 6 months post-baseline
The Emotional Acceptance Scale (Stanton et. al., 2000) will be administered. Thirteen items include statements such as, "I naturally and easily attend to my feelings," "I allow myself to be in touch with my feelings because it is very good for me", and "Knowing they are 'not perfect', I am comfortable with my feelings as they are." Participants indicate percentage of time they believe the statement is true for them ranging from 0 for "never" to 100 for "almost always." The total score is the average for the 13 items (range 0 - 100) and higher scores indicate more emotional acceptance.
Time frame: Baseline, two and 6 months post-baseline
Positive emotional expression is a 7 item subscale of the Emotional Expressiveness Questionnaire (King & Emmons, 1990). Items are rated on a 5-point Likert scale with 0 = Never; 1 = Rarely; 2 = Sometimes; 3 = Frequently; 4 = Always. High scores ndicate a tendency to express emotion.
Time frame: Baseline, two and 6 months post-baseline
The degree to which the participant holds back from talking about cancer-related concerns with others will be measured by asking participants to rate how much each of 11 common cancer concerns is a concern and how much they hold back from talking to others about this concern. The Investigators adapted this scale from Porter and colleagues (Porter, et. al, 2005). A 13-item scale was used that measures the degree to which participants hold back from family and friends. Participants are asked to rate, on a 6-point scale, the degree to which they hold back from discussing issues of concern with friends and family. Scores are averaged to produce a total score, with higher scores indicating greater holding back
Time frame: Baseline, two and 6 months post-baseline
The family and friend version of the perceived negative behavior scale (Manne, Pape, & Taylor, 1999) contains critical responses as well as more subtle responses of others. .Cronbach's alphas have ranged from .87 to .94 in the investigators' work with this patient population (Manne et al., 2019)
Time frame: Baseline, two and 6 months post-baseline
The 10-item Acceptance and Action Questionnaire-II will be used (AAQ-II) (Bond et. al., 2011) to assess avoidance and willingness to accept undesirable thoughts and feelings while acting in congruence with personal values and goals. a 1 = never true up to 7 = always true. Higher total scores mean less flexibility, while lower total scores mean more flexibility
Time frame: Baseline, two and 6 months post-baseline
The 6-item State Hope Scale (SHS; Snyder, Sympson, Ybasco, Borders, Babyak, & Higgins, 1996) measures agency (belief in one's ability to reach goals) and pathways (belief in one's ability to find routes to reach goals). Individuals rate how true or false each statement (e.g., "I can think of many ways to reach my current goals.") is for them right now on a scale of 1 (Definitely false) to 8 (Definitely true). Total scores range from 6-48 and subscale scores range from 3-24.
Time frame: Baseline only
items assessing age, education, ethnicity, occupation, employment status, income, religious affiliation, marital status and length of significant relationship (baseline only).
Time frame: Baseline, two and 6 months post-baseline
Chart reviews at baseline will capture type of cancer
Time frame: Baseline, two and 6 months post-baseline
The WAI Short Form (WAI-S) is a 12 item inventory rated on a 7-point Likert scale (A. O. Horvath, 1981, 2010). The measure has three alliance subscales: Bond, Task, and Goal.
Time frame: Baseline, two and 6 months post-baseline
Chart reviews at baseline will capture time since diagnosis
Time frame: Baseline, two and 6 months post-baseline
Chart reviews at baseline will capture use of medication for pain, depression, anxiety
Time frame: Baseline, two and 6 months post-baseline
Chart reviews at baseline will capture cancer treatment history
Time frame: Baseline, two and 6 months post-baseline
Chart reviews at baseline will capture sleep disturbance
Rutgers, The State University of New Jersey
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06677190
Adnexal Diseases, Cervical Cancer
Boston, Massachusetts, United States
View Trial DetailsNCT04068675
Adnexal Diseases, Cervical Cancer
Chicago, Illinois, United States
View Trial DetailsNCT06483997
Adnexal Diseases, Anemia
Washington D.C., District of Columbia, United States
View Trial DetailsNCT04122235
Adnexal Diseases, Alzheimer Disease
Gjøvik, Oppland, Norway
View Trial Details